Literature DB >> 15888172

Systemic pyoderma gangrenosum responding to infliximab and adalimumab.

V G Hubbard1, A C Friedmann, P Goldsmith.   

Abstract

Pyoderma gangrenosum (PG) is frequently associated with constitutional symptoms as part of a nonspecific inflammatory response. However, extracutaneous discrete aseptic neutrophilic infiltrates are extremely rare. We report a patient with idiopathic PG with splenic and psoas muscle involvement. His disease was extremely aggressive and was unresponsive to conventional immunosuppressive therapy. His cutaneous and extracutaneous PG cleared with infliximab and adalimumab.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888172     DOI: 10.1111/j.1365-2133.2005.06467.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  21 in total

Review 1.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

2.  Development of pyoderma gangrenosum during therapy with infliximab.

Authors:  Natalia Jaimes-López; Verónica Molina; Juan E Arroyave; Luz A Vasquez; Ana C Ruiz; Rodrigo Castaño; Mario H Ruiz
Journal:  J Dermatol Case Rep       Date:  2009-08-24

Review 3.  [What the rheumatologist can learn from the dermatologist-or: nobody can separate good friends : Interfaces of both domains].

Authors:  K Schäkel; A Schirra
Journal:  Z Rheumatol       Date:  2018-08       Impact factor: 1.372

Review 4.  [Pyoderma gangrenosum].

Authors:  K Herberger
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

5.  Refractory postsurgical pyoderma gangrenosum in a patient with Beckwith Wiedemann syndrome: response to multimodal therapy.

Authors:  Faiza Fakhar; Sehrish Memon; Diane Deitz; Richard Abramowitz; Deborah R Alpert
Journal:  BMJ Case Rep       Date:  2013-10-23

6.  Pyoderma gangrenosum with spleen involvement. Review of the literature and case report.

Authors:  Rodica Cosgarea; Simona Corina Senilă; Radu Badea; Loredana Ungureanu
Journal:  J Dermatol Case Rep       Date:  2016-11-13

7.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

8.  Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone.

Authors:  Eva Zold; Arpad Nagy; Katalin Devenyi; Margit Zeher; Zsolt Barta
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

9.  Pyoderma gangrenosum occurring at the peri-ileal pouch-anal anastomosis in a patient with ulcerative colitis: report of a case.

Authors:  Koji Tanaka; Toshimitsu Araki; Yoshiki Okita; Hiroyuki Fujikawa; Mikio Kawamura; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Surg Today       Date:  2012-12-22       Impact factor: 2.549

Review 10.  Adalimumab in dermatology.

Authors:  Pawel Traczewski; Lidia Rudnicka
Journal:  Br J Clin Pharmacol       Date:  2008-07-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.